Immunovia AB, a research company that develops highly accurate blood tests for early detection of cancer and autoimmune diseases, has published results from a study in its development pipeline, published in the co-review -aoisean Journal of Proteome Research. These are the first proteomic data allowing differential analysis of four different inflammatory rheumatic diseases (IRDs).
Early and correct diagnosis of inflammatory rheumatic diseases is currently a clinical challenge due to the various symptoms. The goal of the study was to achieve protein expression profiles differentiating from four systemic IRDs that, if left untreated, can lead to severe and permanent disability, increased morbidity, and premature mortality. A total of 316 serum samples were collected from patients with systemic Lupus Erythematosus (SLE), ANCA-associated systemic vasculitis (SV), Rheumatoid Arthritis (RA), and Sjrom Sjögren (SS), and healthy controls were examined, using reconstituted Immunovia antibody microarray (IMMray ™). A different protein expression profile was analyzed using Wilcoxon’s signature level test and thick biomarker panels could reveal each disease, using advanced bioinformatics and modern classification algorithms.
Lead author Mattias Ohlsson, Professor of Computational Biology and Biological Physics at Lund University, said: “In this study, we were able to identify the individual IRDs that were included. classification with high accuracy, as evidenced by ROC Area Under the Curve (ROC AUC) values between 0.96 and 0.80. The groups of IRDs could be separated from healthy controls at an AUC ROC value of 0.94. We believe this supports the philosophy of using IMMray ™ to reveal the biological complexity of autoimmune diseases. ”
Patrik Dahlen, Head of Immunovia, said: “Today’s autoimmune diseases are a global health issue, affecting millions of people worldwide and there is an urgent need for reformed clinical instruments for early and differential diagnosis. . These findings suggest that the use of a complex approach such as IMMray ™ is particularly suitable for coding multifactorial diseases such as autoimmune diseases. Early diagnosis in turn will help prevent serious organ and tissue related damage. We will include these names and further evaluate them in our self-defense disease detection program. ”
Want more of the latest science news to your inbox? Become a free SelectScience member today >>